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and Johan Lundberg6
Abstract
Background: There is limited real-world data on the economic burden of patients with autosomal dominant polycystic
kidney disease (ADPKD). The objective of this study was to estimate the annual direct and indirect costs of patients with
ADPKD by severity of the disease: chronic kidney disease (CKD) stages 1–3; CKD stages 4–5; transplant recipients; and
maintenance dialysis patients.
Methods: A retrospective study of ADPKD patients was undertaken April–December 2014 in Denmark, Finland, Norway
and Sweden. Data on medical resource utilisation were extracted from medical charts and patients were asked to
complete a self-administered questionnaire.
Results: A total of 266 patients were contacted, 243 (91%) of whom provided consent to participate in the
study. Results showed that the economic burden of ADPKD was substantial at all levels of the disease. Lost
wages due to reduced productivity were large in absolute terms across all disease strata. Mean total annual
costs were highest in dialysis patients, driven by maintenance dialysis care, while the use of
immunosuppressants was the main cost component for transplant care. Costs were twice as high in
patients with CKD stages 4–5 compared to CKD stages 1–3.
Conclusions: Costs associated with ADPKD are significant and the progression of the disease is associated with an
increased frequency and intensity of medical resource utilisation. Interventions that can slow the progression of the
disease have the potential to lead to substantial reductions in costs for the treatment of ADPKD.
Keywords: Polycystic kidney diseases, ADPKD, Health Care Costs, Health Expenditures, Cost of Illness
Background
Autosomal dominant polycystic kidney disease (ADPKD)
is a dominantly inherited systemic disease characterised
by progressive growth of renal cysts. Recent studies in
Europe estimate the prevalence at around one in 3000
people [1, 2], equivalent to fewer than 200,000 cases in the
European Union. While a rare disease overall, ADPKD is
one of the most common hereditary diseases.
Clinical symptoms of renal disease can occur at any age
but typically begin in the third or fourth decade of life [3].
Kidney volume growth is due to cyst expansion and pre-
cedes functional renal deterioration (as measured by
glomerular filtration rate [GFR]) by several decades.
Compensatory hyperfiltration in surviving nephrons
initially maintains renal function near normal values.
Around 50% of patients require renal replacement therapy
due to kidney failure, which typically develops in the
fourth to sixth decade of life [3]. Conventional treatments
are tailored to reduce morbidity due to complications of
the disease [4]. However, new treatment options slowing
down the progression of the disease have now become
available [5]. Transplantation is the treatment of choice
for end-stage renal disease (ESRD) in ADPKD [4]. Still
only a limited number of patients with ESRD undergo
transplantation instead of dialysis as initial renal replacement
therapy [6].
There is sparse information on the economic burden of
ADPKD. One study showed an association between direct
medical costs and advanced renal dysfunction in patients
with polycystic kidney disease who were free of indications
of dialysis or transplantation at baseline [7]. A recent study
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of early-stage ADPKD patients with normal kidney func-
tion, found that these patients added a sizable economic
burden to the health care system relative to the general
population [8]. In a cross-sectional analysis, ADPKD
patients, compared to chronic kidney disease (CKD)
patients, were found to be younger and generally
healthier [9]. However, kidney-related complications
and major kidney procedures were more common
among ADPKD patients. Further, a retrospective study
of medical resource utilisation in ESRD showed that
ADPKD patients were younger at dialysis initiation and
had lower medical costs compared to control patients
with ESRD etiologies other than ADPKD [10].
Cost estimates of ADPKD have been predominantly
based on US reimbursement claims data and focused on
direct medical resource utilisation for a subset of the
population. The objective of this study was to estimate
the annual direct and indirect costs of patients with
ADPKD, by severity of the disease, in the Nordics.
Methods
Study design
This was a cross-sectional study of patients with
ADPKD based on data collected from medical charts
and patient self-administered questionnaires. Nine
nephrology clinics participated; four in Denmark, one
in Finland, two in Norway and two in Sweden.
Between April and December 2014, we screened and
enrolled convenience samples of subjects from each
clinic. Patients were recruited by phone or in-person
during routine clinical care.
Ethics approvals for the study were granted by the
Helsinki University Hospital Ethical Review Board, the
Regional Committee of Medical and Health Research
Ethics in Oslo (REC South East) and the Regional
Ethical Review Board in Stockholm. While the study
was reported to the Danish Health and Medicines
Authority, formal ethics approval was not required due
to the non-interventional design. The study protocol
and consent procedures were also reviewed and
approved by the participating clinics.
Sample and inclusion criteria
Subjects were enrolled into four mutually exclusive
strata using a hierarchical approach:
1. maintenance dialysis: patients currently on dialysis
with or without transplanted kidney
2. transplant recipients: patients with a functioning
transplanted kidney, currently not on dialysis
3. CKD stages 4–5: patients not currently on dialysis/
no previous transplant
4. CKD stages 1–3: patients not currently on dialysis/
no previous transplant
Disease severity among ADPKD patients was determined
using the estimated GFR (eGFR), as calculated by each re-
spective laboratory; eGFR <30 ml/min/1.73m2 for CKD
stages 4–5 and eGFR ≥30 ml/min/1.73m2 for CKD stages
1–3. The most recent laboratory value was used to estab-
lish disease severity at enrolment date. Enrolment of pa-
tients was tracked in order to achieve a balanced
recruitment across the four groups.
Subjects were eligible for enrolment in the study if they
were 18 years of age or older and had been managed for
ADPKD at the clinic during the past 12 months. Further-
more, participants were required to have had an eGFR
value recorded in the past 12 months (not applicable if on
dialysis). Subjects were excluded if they had been involved
in a clinical trial in the past 12 months that resulted in a
change in the standard of care received. Patients on main-
tenance dialysis were required to have had initiated dialysis
at least six months prior to enrolment. Similarly, patients
with a working kidney transplant were required to have
had undergone the transplant procedure at least six
months prior to enrolment. Finally, informed written
consent was required for participation in the study.
Data collection
Data were extracted from medical charts using a
standardised case report form (CRF) and complemented
with a self-administered questionnaire [see Additional files
1 and 2]. The CRF and questionnaire were matched for
each subject using anonymised subject identifiers.
The standardised CRF allowed for uniform collection of
demographic data, disease history and annual ADPKD-
related resource utilisation. The CRF covered the 12-
month period prior to patient enrolment (enrolment date).
The questionnaire, completed by patients, included com-
plementary questions on ADPKD-related healthcare ser-
vices received in the past four weeks outside of the primary
nephrology clinic, including informal care. Indirect morbid-
ity measures in terms of time missed from work and im-
pairment of work productivity were obtained using the
Work Productivity and Activity Impairment (WPAI:GH)
questionnaire [11].
Cost estimation
A societal perspective was used to estimate total costs. We
summarised both direct and indirect annual costs related
to ADPKD. Resources used in the past 12 months were
quantified for each patient and multiplied by unit costs to
derive total annual costs. Unit costs for healthcare services
(e.g. primary care visit or blood transfusion) were obtained
from local and national pricelists as presented in Table 1.
Additional costs were derived from public reports and na-
tional statistics offices (e.g. daily cost of peritoneal dialysis
or gross earnings/employment rates).
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Medical resource utilisation was analysed in terms of
hospitalisation, outpatient visits, primary care visits, trans-
portation, surgical procedures, diagnostic tests and
pharmacotherapy. Pharmacotherapy costs were estimated
using conservative dosage estimates as per the drug label
[12] for the following classes: antihypertensives, phosphate
binders, erythropoiesis-stimulating agents (ESAs), analge-
sics for kidney pain, vitamin D analogues and immunosup-
pressive agents.
Indirect costs included informal care and productivity
loss. Cost of informal care was based on hours of help from
family and friends in the patient’s home and calculated
using data on average national gross earnings. Productivity
loss was estimated using the human capital approach, tak-
ing the patient’s perspective and counting every lost hour of
work as lost production and income [42]. Age- and sex-
dependent gross earnings and employment rates were ob-
tained from official statistics offices in each country, with
employment overheads and benefits added on top. It was
assumed that ADPKD patients would have had the same
employment rate as the general population had they not
been ill.
Table 1 Data sources for estimating costs
Type of data Country Source
Direct costsa Denmark Danish Medicines Agency [13]
Statens Serum Institut [14]
The Capital Region of Denmark [15]
Rigshospitalet [16]
Finland Pharmaceuticals Pricing Board [17]
The Social Insurance Institution of Finland [18]
The Hospital District of Helsinki and
Uusimaa [19, 20]
National institute for health and welfare [21]
Kuopio University Hospital [22]
Norway Norwegian Medicines Agency [23]
Norwegian Directorate of Health [24, 25]
Ministry of Health and Care Services [26]
Sweden Dental and Pharmaceutical Benefits
Agency [27]
Swedish Association of the Pharmaceutical
Industry [12]
Region Skåne [28]
Stockholm County Council [29]
Indirect costs Denmark Statistics Denmark [30, 31]
Eurostat [32]
KPMG [33]
Finland Statistics Finland [34, 35]
Norway Statistics Norway [36–38]
KPMG [33]
Sweden Statistics Sweden [39, 40]
Swedish Tax Agency [41]
aTransportation costs (to and from haemodialysis) were based on answers in
the self-administered questionnaire: taxi, 15 km; public transport, 30 min
duration; car, 30 km
Table 2 Patient characteristics at enrolment date
Patient
characteristic
CKD 1–3
(n = 64)
CKD 4–5
(n = 55)
Dialysis
(n = 61)
Transplant
(n = 63)
P value
Country, n (%)a <0.0001
Denmark 26 (41) 32 (58) 32 (52) 28 (44)
Sweden 19 (30) 12 (22) 14 (23) 13 (21)
Norway 19 (30) 11 (20) 4 (7) 16 (25)
Finland 0 (0) 0 (0) 11 (18) 6 (10)
Sex (female), n (%) 38 (59) 29 (53) 33 (54) 31 (49) 0.7144
Age (years),
mean ± SDb
52 ± 13 57 ± 12 64 ± 10 59 ± 10 <0.0001
BMI (≥30 kg/m2),
n (%)
10 (16) 11 (20) 15 (25) 14 (22) 0.7667
Currently employed,
n (%)
40 (63) 27 (49) 13 (21) 28 (44) <0.0001
Currently employed
(aged <65 years),
n (%)
40 (78) 27 (64) 12 (38) 26 (59) <0.0001
Comorbidities (≥1),
n (%)
43 (67) 44 (80) 61 (100) 45 (76) <0.0001
Dialysis in the past
12 months, n (%) a
. . 61 (100) 5 (8) <0.0001
Haemodialysis . . 51 (84) 5 (100) 1.0000
Peritoneal dialysis . . 12 (20) 0 (0) 0.5754
P values calculated with χ2 test unless otherwise specified
SD standard deviation, BMI body mass index
aFisher’s exact test
bKruskal–Wallis test
Table 3 Annual resource utilisation
Mean resource utilisation, past 12 months ± SD CKD 1–3 (n = 64) CKD 4–5 (n = 55) Dialysis (n = 61) Transplant (n = 63) P value
Number of hospitalisations 0.2 ± 0.6 0.5 ± 1.1 1.8 ± 2.3 0.6 ± 1.0 <0.0001
Number of hospital days 0.9 ± 3.1 2.3 ± 6.9 9.2 ± 13.6 4.4 ± 10.2 <0.0001
Number of hospital days (at least one hospitalisation) 6.9 ± 6.5 8.7 ± 11.6 15.7 ± 14.7 12.4 ± 14.1 0.1878
Number of outpatient visitsa 5.2 ± 10.5 8.2 ± 17.1 15.2 ± 24.1 11.6 ± 13.7 <0.0001
Number of primary care visitsb 2.2 ± 5.5 3.8 ± 16.8 1.9 ± 8.0 1.2 ± 3.8 0.6401
Number of surgical procedures 0.1 ± 0.4 0.3 ± 0.7 1.6 ± 3.1 0.6 ± 1.3 <0.0001
Hours of help: Healthcare professionalb 27.0 ± 149.8 1.8 ± 9.6 17.1 ± 61.2 6.4 ± 40.4 0.1155
Hours of help: Home care assistantb 0.0 ± 0.0 0.2 ± 1.8 27.6 ± 132.6 0.8 ± 3.8 <0.0001
Hours of help: Family member or friendb 3.1 ± 18.2 27.0 ± 84.6 104.8 ± 325.1 11.0 ± 31.0 <0.0001
P values calculated with Kruskal–Wallis test
aExcluding visits for maintenance dialysis
bBased on the past 4 weeks, self-reported
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Annual cost estimates were derived using national
cost data and expressed in the local currency of each
respective country (2014 values).
Statistical analyses
Summary statistics were calculated, including means and
standard deviations (SDs) for continuous variables and
frequency distributions for categorical variables. We
presented costs as means and used non-parametric boot-
strapping procedures to derive 95% confidence intervals.
Differences across strata were evaluated using the
Kruskal–Wallis and χ2/Fisher’s exact tests as appropriate.
Resource utilisation in the past four weeks, as captured in
the self-administered questionnaire, was extrapolated to
one year. Data management and analysis were performed
using Stata 12.1 (StataCorp LP, College Station, TX, USA).
Table 4 Annual drug utilisation
Proportion (%) of
patients using drug
class, past 12 months
CKD 1–3
(n = 64)
CKD 4–5
(n = 55)
Dialysis
(n = 61)
Transplant
(n = 63)
P value
Antihypertensives 84 98 84 87 0.0275
Phosphate binders 0 21 95 14 <0.0001
ESAs 2 13 80 15 <0.0001
Analgesics for
kidney paina
17 28 25 17 0.4149
Vitamin D analogsa 14 57 97 43 <0.0001
Immunosupressantsa 0 0 7 100 <0.0001
Other drugs 19 36 90 41 <0.0001
P values calculated with Fisher’s exact test unless otherwise specified
ESA Erythropoiesis-stimulating agent
aχ2 test
Table 5 Productivity loss
WPAI-GHa,
percent
(%) ± SD
CKD 1–3
(n = 61)
CKD 4–5
(n = 53)
Dialysis
(n = 57)
Transplant
(n = 63)
P value
Activity
impairment
due to health
16.7 ± 24.4 29.4 ± 28.0 52.6 ± 27.2 30.4 ± 27.5 <0.0001
Overall work
impairment
due to health
8.7 ± 14.6 22.8 ± 28.7 41.8 ± 33.5 16.4 ± 23.1 0.0025
Work time
missed due
to health
(absenteeism)
4.2 ± 17.3 8.3 ± 18.9 25.9 ± 32.8 4.6 ± 19.6 0.0014
Impairment
while working
due to health
(presenteeism)
7.4 ± 12.2 18.8 ± 24.1 25.8 ± 23.9 15.0 ± 20.8 0.0109
P values calculated with Kruskal–Wallis test
WPAI-GH Work Productivity and Activity Impairment-General Health
aPatients were asked to estimate impairment in the past 7 days
(recall period)
Table 6 Annual costs in Danish krone (Denmark)
Costs in DKK,
mean (95% CI)
CKD 1–3 (n = 64) CKD 4–5 (n = 55) Dialysis (n = 61) Transplant (n = 63) P value
Direct costs 28,022 (14,728–50,835) 47,203 (35,863–63,990) 667,362 (623,398–720,640) 196,114 (159,055–237,980) <0.0001
Hospitalisations 4736 (1611–10,505) 12,224 (4810–24,391) 50,954 (34,240–71,642) 23,881 (12,072–40,151) <0.0001
Outpatient care visits 5596 (3810–7867) 9483 (6889–14,515) 15,802 (11,175–21,341) 14,219 (10,992–18,453) <0.0001
Primary care visits 1558 (779–2761) 2719 (712–7252) 1144 (163–2942) 791 (317–1741) .5094
Surgical procedures 2183 (125–7519) 6938 (2660–13,242) 31,596 (18,141–50,394) 4228 (1812–7559) <0.0001
Diagnostic tests 1591 (1055–2225) 1803 (1239–2542) 6081 (4851–7544) 3464 (2374–5095) <0.0001
Home care/medical assistance 9838 (38–28,949) 717 (62–1940) 12,399 (4417–23,648) 2503 (313–7919) .0001
Routine dialysis care – – 441,221 (417,652–462,446) 14,377 (3783–28,905) <0.0001
Haemodialysis transportation – – 41,146 (33,117–49,306) 214 (0–1068) <0.0001
Drug use 2520 (1404–3856) 13,318 (9605–17,716) 67,020 (57,869–79,028) 132,438 (110,082–158,657) <0.0001
Antihypertensives 391 (295–507) 476 (394–559) 343 (272–420) 401 (303–534) .0560
Phosphate binders – 1351 (656–2160) 10,551 (8212–13,158) 521 (123–1242) <0.0001
ESAs 60 (0–245) 3366 (1286–5953) 23,281 (19,497–26,558) 3449 (1459–6102) <0.0001
Analgesics for kidney pain 17 (5–39) 90 (21–253) 182 (26–534) 13 (2–37) .1069
Vitamin D analogues 2004 (937–3379) 6955 (5201–8861) 13,309 (12,162–14,207) 4593 (3129–6257) <0.0001
Immunosupressants – – 5699 (312–14,111) 122,984 (100,943–149,412) <0.0001
Other drugs 48 (11–110) 1081 (157–2500) 13,655 (10,825–16,513) 477 (194–932) <0.0001
Indirect costs 51,523 (32,278–75,631) 94,631 (65,117–126,721) 100,970 (67,789–132,323) 81,688 (55,334–110,676) .0726
Productivity loss 51,224 (31,835–75,332) 92,083 (63,079–123,547) 91,373 (59,420–122,164) 80,647 (54,460–109,503) .3032
Informal care 299 (0–896) 2548 (873–5141) 9597 (3801–19,465) 1041 (415–1891) <0.0001
Total costs 79,544 (54,826–109,204) 141,834 (105,601–181,449) 768,332 (707,301–830,831) 277,802 (227,251–333,023) <0.0001
P values calculated with Kruskal–Wallis test
DKK Danish krone, ESA erythropoiesis-stimulating agent, CI confidence interval (bias corrected)
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Results
Demographic and clinical characteristics
A total of 266 patients were contacted. Of these 243 (91%)
provided consent to participate and were enrolled into the
four disease strata: CKD stages 1–3 (n = 64), CKD stages
4–5 (n = 55), transplant (n = 61), and dialysis (n = 63). Over-
all, 241 (99%) of participants completed the questionnaire.
Dialysis and transplant patients tended to be older than
patients in earlier stages of the disease; those younger than
65 years were 80% in patients with CKD stages 1–3, 76%
in CKD stages 4–5, 54% in dialysis patients and 70% in
transplant recipients. Mean age for initiation of dialysis
was 59 years in the dialysis stratum and the average age at
the time of kidney transplantation was 52 years. Among
those on dialysis, only two patients (3%) had received both
haemodialysis and peritoneal dialysis in the past 12 months.
No differences between disease strata were seen in sex and
BMI (Table 2). Employment rates were lowest in the dialy-
sis stratum (21%), with corresponding rates of 44% in
transplant recipients, 49% in CKD stages 4–5 and 63% in
CKD stages 1–3.
Medical resource utilisation
Medical resource utilisation differed substantially between
disease strata (Table 3). In general, dialysis patients had the
highest number of hospitalisations and outpatient visits,
followed by transplant recipients and other dialysis-
independent patients. This difference, however, was not
observed for primary care visits, as reported in the self-
administered questionnaire.
Only 8% of CKD stages 1–3 patients had a surgery
related to ADPKD in the past year, compared to
18% of CKD stages 4–5 patients, 29% of transplant
recipients and 49% of dialysis patients. Consequently,
there was a significant difference in the mean num-
ber of surgical procedures in the past year between
the disease strata, ranging from 0.1 in patients with
CKD stages 1–3 to 1.6 in dialysis patients. Among
transplant recipients, 10% had received the
transplant in the past year. Similarly, 25% of dialysis
patients had initiated treatment in the past year.
Dialysis patients were generally prescribed more drugs
compared to the other disease states; 95% of dialysis pa-
tients used phosphate binders, 80% used erythropoiesis-
stimulating agents (ESAs) and 97% were prescribed vita-
min D analogues (Table 4). Analgesics for kidney pain
were, however, most common in CKD stages 4–5, used by
27% compared to 16–23% in the other disease strata.
Almost all patients with CKD stages 4–5 (98%) were
prescribed antihypertensives.
Among dialysis patients 59% travelled by taxi to
receive their treatment, while 35% drove and 6% used
Table 7 Annual costs in euro (Finland)
Costs in EUR, mean (95% CI) CKD 1–3 (n = 64) CKD 4–5 (n = 55) Dialysis (n = 61) Transplant (n = 63) P value
Direct costs 3676 (2223–6190) 5883 (4588–7701) 64,811 (60,460–70,417) 20,305 (16,228–25,166) <0.0001
Hospitalisations 507 (172–1125) 1309 (515–2611) 5455 (3666–7670) 2557 (1283–4299) <0.0001
Outpatient care visits 1159 (843–1569) 2057 (1606–2871) 3203 (2329–4230) 3197 (2502–4155) <0.0001
Primary care visits 237 (117–403) 414 (84–1097) 174 (50–548) 121 (48–265) .5094
Surgical procedures 249 (15–794) 511 (154–1098) 2562 (1211–5119) 1009 (435–1956) <0.0001
Diagnostic tests 191 (125–263) 237(166–321) 659 (511–843) 354 (251–496) <0.0001
Home care/medical assistance 1048 (4–3049) 74 (5–204) 1093 (384–2044) 260 (28–837) .0002
Routine dialysis care – – 42,900 (40,609–44,964) 1398 (368–2810) <0.0001
Haemodialysis transportation – – 4090 (3184–5080) 13 (0–25) <0.0001
Drug use 284 (175–419) 1281 (1008–1600) 4675 (4040–5512) 11,396 (9404–13,944) <0.0001
Antihypertensives 68 (54–86) 113 (95–132) 73 (60–86) 96 (78–117) .0020
Phosphate binders – 225 (103–362) 1266 (1006–1554) 65 (15–148) <0.0001
ESAs 4 (0–15) 204 (78–361) 1413 (1181–1611) 209 (89–370) <0.0001
Analgesics for kidney pain 3 (1–7) 14 (5–30) 12 (4–25) 4 (0–12) .1329
Vitamin D analogues 198 (93–335) 689 (516–878) 1318 (1207–1407) 455 (310–620) <0.0001
Immunosupressants – – 440 (26–1076) 10,469 (8516–12,955) <0.0001
Other drugs 10 (3–27) 36 (17–61) 154 (126–183) 99 (48–171) <0.0001
Indirect costs 4863 (2986–7132) 9904 (6738–13,319) 7674 (5195–10,042) 7585 (5125–10,494) .0925
Productivity loss 4835 (2959–7104) 9667 (6586–13,018) 6783 (4586–8815) 7488 (5058–10,382) .2742
Informal care 28 (0–83) 237 (79–475) 891 (353–1807) 97 (38–176) <0.0001
Total costs 8539 (6042–11,631) 15,787 (12,006–20,008) 72,486 (67,053–79,025) 27,890 (22,669–33,722) <0.0001
P values calculated with Kruskal–Wallis test
EUR euro, ESA erythropoiesis-stimulating agent, CI confidence interval (bias corrected)
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public transport. Forty-three percent travelled for at
least 30 min one-way to receive treatment.
Activity and work impairment
The levels of general daily activity impairment and prod-
uctivity impairment due to health problems differed with
disease severity. Activity impairment was highest among
dialysis patients with 53% but also substantial at 30% in
both patients with CKD stages 4–5 and among transplant
recipients (Table 5). Among those employed, an average of
4–26% of work time was missed due to health problems,
while patients estimated 7–26% of time lost while at work,
depending on disease severity. Taken together, overall work
impairment due to health was significantly different be-
tween disease strata. Work impairment was highest among
dialysis patients (42%), followed by CKD stages 4–5 (23%),
transplant recipients (16%) and CKD stages 1–3 (9%).
Annual costs associated with ADPKD
Costs are presented by disease severity and expressed
in each respective local currency (Tables 6, 7, 8 and
9). Average total annual costs were highest for dialysis
patients, followed by transplant recipients, patients in
CKD stages 4–5 and CKD stages 1–3 (P < 0.0001, for
all countries). Compared to CKD stages 1–3, annual
costs were almost twice as high in CKD stages 4–5,
two to three times higher in transplant recipients, and
seven to nine times higher in dialysis patients. Differences
between disease strata were even more pronounced when
looking at direct costs alone (P < 0.0001, for all countries).
Direct costs were almost twice as high in patients with
CKD stages 4–5 compared to stages 1–3, but around
six times higher among transplant recipients and 21
times higher among dialysis patients. Direct medical
costs were substantial among dialysis patients, with
routine dialysis care alone accounting over half of total
costs. Productivity loss was a driver of costs across all
stages of ADPKD, and especially substantial at around
two-thirds of total costs in patients with CKD stages
1–3 and 4–5.
Discussion
In this study we enrolled 243 ADPKD patients from nine
nephrology clinics in Denmark, Finland, Norway and
Sweden. For these patients we collected and analysed
data from medical charts and self-administered ques-
tionnaires. Our findings showed that the economic
burden of ADPKD was substantial at all levels of dis-
ease and that progression of ADPKD was associated
with an increased frequency and intensity of medical
resource utilisation.
Table 8 Annual costs in Norwegian krone (Norway)
Costs in NOK, mean (95% CI) CKD 1–3 (n = 64) CKD 4–5 (n = 55) Dialysis (n = 61) Transplant (n = 63) P value
Direct costs 38,676 (18,712–69,343) 80,145 (51,159–118,538) 851,277 (765,334–959,286) 185,108 (131,915–251,557) <0.0001
Hospitalisations 12,898 (4387–28,610) 33,291 (13,098–66,704) 138,766 (93,249–195,108) 65,036 (32,637–109,347) <0.0001
Outpatient care visits 4425 (3355–5859) 8085 (6588–10,612) 12,050 (8956–15,673) 12,840 (10,094–16,706) <0.0001
Primary care visits 691 (345–1224) 1205 (246–3192) 507 (145–1594) 351 (140–772) .5094
Surgical procedures 4209 (89–15,018) 23,660 (10,359–40,439) 106,888 (67,415–153,360) 6798 (1790–14,265) <0.0001
Diagnostic tests 1652 (1100–2273) 1959 (1417–2622) 6423 (5132–8002) 3359 (2450–4587) <0.0001
Home care/medical assistance 12,317 (48–36,245) 885 (66–2396) 14,151 (5074–27,170) 3090 (359–9872) .0002
Routine dialysis care – – 495,052 (468,607–518,867) 16,131 (4245–32,431) <0.0001
Haemodialysis transportation – – 32,460 (25,631–39,573) 128 (0–256) <0.0001
Drug use 2483 (1472–3707) 11,060 (8445–14,068) 44,980 (39,925–51,304) 77,375 (64,093–95,936) <0.0001
Antihypertensives 530 (435–640) 715 (621–808) 522 (433–617) 567 (461–687) .02459
Phosphate binders – 1158 (565–1850) 8072 (6345–9932) 418 (102–944) <0.0001
ESAs 36 (0–148) 2036 (778–3600) 14,079 (11,772–16,055) 2086 (827–3610) <0.0001
Analgesics for kidney pain 16 (6–31) 103 (33–251) 104 (29–256) 33 (3–98) .1053
Vitamin D analogues 1833 (857–3090) 6360 (4761–8104) 12,170 (11,121–12,991) 4200 (2861–5722) <0.0001
Immunosupressants – – 2741 (290–6569) 69,324 (56,582–87,711) <0.0001
Other drugs 68 (19–164) 688 (181–1422) 7292 (5804–8788) 746 (353–1326) <0.0001
Indirect costs 111,441 (70,268–157,539) 204,324 (143,043–268,451) 215,588 (144,283–280,047) 182,164 (125,099–242,812) .0604
Productivity loss 110,892 (70,085–157,480) 199,644 (139,793–263,028) 197,961 (129,783–259,106) 180,251 (123,425–241,038) .2452
Informal care 548 (0–1645) 4680 (1603–9442) 17,627 (7001–35,752) 1913 (761–3473) <0.0001
Total costs 150,117 (104,759–202,958) 284,469 (206,680–373,107) 1,066,865 (950,458–1,204,094) 367,272 (278,949–466,269) <0.0001
P values calculated with Kruskal–Wallis test
NOK Norwegian krone, ESA erythropoiesis-stimulating agent, CI confidence interval (bias corrected)
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Mean total direct and indirect costs were approximately
twice as high in patients with CKD stages 4–5 compared
to CKD stages 1–3. Resource utilisation increased substan-
tially as patients progressed to ESRD, with costs among
dialysis patients greatly exceeding that of kidney transplant
recipients. The use of immunosuppressants accounted for
around half of costs in transplant recipients. Similarly,
maintenance dialysis care alone accounted for over half of
total costs in dialysis patients, who had the highest number
of hospitalisations and outpatient visits. Primary care visits
were more frequent in earlier stages of the disease. Lost
wages due to reduced productivity were large in absolute
terms across all disease strata. General daily activity impair-
ment due to health was highest among dialysis patients
who reported an average reduction in activity of over 50%.
Activity impairment was also substantial in transplant
recipients and in patients with CKD stages 4–5, both at
around 30%.
Some limitations of our study should be noted.
Selection bias may be an issue as with any observational
study. No randomisation was performed and primarily
patients who actively sought health care were included.
Not all patients in earlier stages of the disease are
followed by nephrology clinics and the study design lim-
ited the inclusion of transplant recipients to those with a
functioning transplant, thus potentially underestimating
costs in patients with advanced disease. A proportion of
patients with ESRD initiated treatment within 12 months
of the enrolment date; however, sensitivity analyses
revealed an insignificant impact on mean total costs.
Our study adds to the limited and fragmented literature
on cost estimates of ADPKD. To our knowledge this is
the first study to provide cost data on an ADPKD popu-
lation that includes both early stages of the disease,
stratified by renal function, and patients with ESRD. A
further strength of this study is the enrolment of pa-
tients with physician-confirmed diagnosis of ADPKD.
Furthermore, in addition to data extraction from med-
ical charts, a self-administered questionnaire, including
the WPAI:GH, was used to capture resource utilisation
outside of the nephrology clinic and to estimate indirect
costs in terms of productivity loss and caregiver support.
Finally, we achieved a high response rate with 91% of
invited patients agreeing to participate in the study.
Conclusions
We provide a thorough description of the medical resource
utilisation and costs associated with ADPKD across all
stages of the disease. Our findings confirm the association
between economic burden and progression of ADPKD [7].
Costs were highest in dialysis patients, driven by mainten-
ance dialysis care, while the use of immunosuppressants
Table 9 Annual costs in Swedish krona (Sweden)
Costs in SEK, mean (95% CI) CKD 1–3 (n = 64) CKD 4–5 (n = 55) Dialysis (n = 61) Transplant (n = 63) P value
Direct costs 28,820 (16,123–50,689) 48,624 (36,718–65,151) 712,482 (668,060–766,530) 173,199 (135,833–218,165) <0.0001
Hospitalisations 3812 (1297–8456) 9840 (3871–19,716) 41,015 (27,561–57,668) 19,223 (9717–32,319) <0.0001
Outpatient care visits 5878 (4291–7943) 10,457 (8193–14,512) 16,221 (11871–21,402) 16,288 (12,728–21,120) <0.0001
Primary care visits 1178 (589–2088) 2056 (539–5484) 865 (124–2225) 598 (120–1077) .5094
Surgical procedures 3349 (187–10,713) 7135 (1620–15,769) 31,431 (16,065–51,975) 8131 (3603–14,557) <0.0001
Diagnostic tests 2847 (2244–3509) 5810 (4535–7332) 25,140 (21,308–29,294) 10,987 (8119–14,700) <0.0001
Home care/medical assistance 9442 (37–27,461) 675 (47–1850) 10,525 (3734–20,134) 2359 (263–7537) .0002
Routine dialysis care – – 488,009 (461940–511,484) 15,901 (4185–32,472) <0.0001
Haemodialysis transportation – – 37,145 (30,444–43,657) 269 (0–1344) <0.0001
Drug use 2313 (1333–3490) 12,651 (9110–16,825) 62,131 (54,647–71,169) 99,443 (80,719–125,735) <0.0001
Antihypertensives 419 (341–513) 666 (556–784) 503 (415–603) 583 (451–756) .0282
Phosphate binders – 1244 (598–1996) 9788 (7577–12,262) 472 (108–1151) <0.0001
ESAs 63 (0–257) 3535 (1350–6252) 24,450 (20,476–27,892) 3622 (1533–6409) <0.0001
Analgesics for kidney pain 14 (5–26) 102 (28–255) 78 (21–193) 15 (2–37) .1032
Vitamin D analogues 1776 (824–2952) 6162 (4613–7852) 11,792 (10,796–12,592) 4069 (2756–5544) <0.0001
Immunosupressants – – 3579 (291–8847) 90,205 (72,049–117,127) <0.0001
Other drugs 41 (10–95) 942 (135–2184) 11,941 (9447–14,436) 477 (202–909) <0.0001
Indirect costs 64,259 (39,484–92,072) 128,541 (90,007–169,626) 124,957 (85,289–162,184) 112,688 (77,160–150,663) .0438
Productivity loss 63,963 (39,446–91,997) 126,019 (88,140–165,959) 115,458 (77,012–150,462) 111,658 (75,795–149,420) .1842
Informal care 296 (0–887) 2522 (864–5088) 9499 (3762–19,266) 1031 (410–1871) <0.0001
Total costs 93,079 (64,756–125,857) 177,165 (131,147–227,131) 837,438 (771,457–903,231) 285,887 (228,017–352,229) <0.0001
P values calculated with Kruskal–Wallis test
SEK Swedish krona, ESA erythropoiesis-stimulating agent, CI confidence interval (bias corrected)
Eriksson et al. BMC Health Services Research  (2017) 17:560 Page 7 of 9
was the main cost component for transplant care. Costs
were twice as high in patients with CKD stages 4–5 com-
pared to CKD stages 1–3. Consequently, interventions that
can slow the progression of the disease have the potential
to lead to substantial reductions in costs for the treatment
of ADPKD.
Additional files
Additional file 1: QR ADPKD CRF 20140331 Final v1.1.pdf – Case report
form (CRF) – Questionnaire used to collect data from patients’ medical
charts. (PDF 85 kb)
Additional file 2: QR ADPKD Additional Questions 20140205 Eng.pdf –
Self-administered questionnaire – Questionnaire administered to patients.
(PDF 16 kb)
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